Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,509
  • Shares Outstanding, K 9,131
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,400 K
  • 60-Month Beta 3.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.19 +15.13%
on 11/20/19
1.65 -16.97%
on 11/07/19
-0.25 (-15.43%)
since 11/06/19
3-Month
1.19 +15.13%
on 11/20/19
2.25 -39.11%
on 09/11/19
-0.68 (-33.17%)
since 09/06/19
52-Week
0.80 +71.25%
on 12/26/18
7.39 -81.46%
on 03/14/19
+0.07 (+5.38%)
since 12/06/18

Most Recent Stories

More News
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.37 (-0.72%)
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research...

ATOS : 1.37 (-0.72%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.37 (-0.72%)
JNJ : 140.38 (+0.59%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.37 (-0.72%)
JNJ : 140.38 (+0.59%)
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary...

ATOS : 1.37 (-0.72%)
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.37 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 1.48
1st Resistance Point 1.42
Last Price 1.37
1st Support Level 1.34
2nd Support Level 1.32

See More

52-Week High 7.39
Fibonacci 61.8% 4.87
Fibonacci 50% 4.09
Fibonacci 38.2% 3.32
Last Price 1.37
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar